A Phase IIb Study of AZD5462 in Patients with Chronic Heart Failure - LUMINARA

Study identifier:D9090C00008

ClinicalTrials.gov identifier:NCT06299826

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure

Medical condition

Chronic heart failure

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD5462, Placebo

Sex

All

Estimated Enrollment

360

Study type

Interventional

Age

18 Years - 85 Years

Date

Study Start Date: 04 Jun 2024
Estimated Primary Completion Date: 24 Nov 2025
Estimated Study Completion Date: 24 Nov 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria